title: [New concept for ALK negative anaplastic large cell lymphoma].
abstract: ALK negative anaplastic large cell lymphoma (ALK(-) ALCL) lacks the specific expression of ALK protein, although it also strongly expresses CD30 and resembles the morphologic characteristics of ALK positive anaplastic large cell lymphoma (ALK(+) ALCL). Recently, some new researches indicate that there exist molecular and genetic differences between these two types of ALCL. Moreover, the treatment response, prognosis, and long-term survival of ALK(-) ALCL are far worse than that of ALK(+) ALCL, such as ALK(-) ALCL is associated with older age persons, B group syndrome, disease advanced stage, high International Prognostic Index (IPI) and poor prognosis (< 49% 5-year survival). As a consequence, some new advances on basis (cell morphology and tissue pathology, immunophenotypes, cell genetics and molecular marker), diagnosis and treatment of ALK(-) ALCL are summarized in this review.
authors.affiliation: Department of Hematology, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Tang
authors.forename: Xiao-Lan
authors.initials: XL
authors.lastname: Shi
authors.forename: De-Pei
authors.initials: DP
authors.lastname: Wu
mesh_terms: D014408:Biomarkers, Tumor; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000145:classification* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor